News Releases

All Releases
View Summary Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2014
Jul 21, 2014
PDF 5.6 KB Add to Briefcase
View Summary Johnson & Johnson Announces $5 Billion Share Repurchase Program
Jul 21, 2014
PDF 7.6 KB Add to Briefcase
View Summary Johnson & Johnson Reports 2014 Second-Quarter Results:
Jul 15, 2014
PDF 64.5 KB Add to Briefcase
View Summary Janssen Pharmaceuticals Seeks Expanded Label for Once-Monthly INVEGA® SUSTENNA® (paliperidone palmitate) to Show Delayed Time to Relapse Compared to Daily Oral Schizophrenia Therapies
Jul 14, 2014
PDF 70.0 KB Add to Briefcase
View Summary CEO and Chairman of UPS, D. Scott Davis, Joins Johnson & Johnson Board of Directors
Jul 7, 2014
PDF 6.7 KB Add to Briefcase
View Summary Cordis Corporation Launches SABER PTA Dilatation Catheter to Complement Portfolio of Peripheral Arterial Disease Treatments
Jul 1, 2014
PDF 9.8 KB Add to Briefcase
View Summary Johnson & Johnson Completes Divestiture Of Ortho-Clinical Diagnostics To The Carlyle Group
Jun 30, 2014
PDF 6.8 KB Add to Briefcase
View Summary Janssen Submits Eu Marketing Application For Velcade® (Bortezomib) In Mantle Cell Lymphoma
Jun 27, 2014
PDF 63.2 KB Add to Briefcase
View Summary Janssen Announces License Agreement With Vertex to Develop Novel Treatment for Influenza A
Jun 18, 2014
PDF 12.6 KB Add to Briefcase
View Summary Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
Jun 17, 2014
PDF 7.6 KB Add to Briefcase
View Summary VELCADE® Data At EHA 2014 Highlight Efficacy In Newly-Diagnosed Mantle Cell Lymphoma And Reinforce Its Role As A Backbone Of Multiple Myeloma Therapy
Jun 16, 2014
PDF 67.2 KB Add to Briefcase
View Summary Janssen Collaborates With ViiV Healthcare To Develop Two-Drug Single Tablet Regimen For The Maintenance Treatment Of People Living With HIV
Jun 12, 2014
PDF 18.6 KB Add to Briefcase
View Summary European Commission Approves SYLVANT® (siltuximab) as a Treatment for Patients with Multicentric Castleman's Disease (MCD)
Jun 5, 2014
PDF 17.8 KB Add to Briefcase
View Summary INVEGA® receives European Commission approval to extend its adult indication for treatment of schizophrenia to include adolescents aged 15 years and older
Jun 4, 2014
PDF 64.6 KB Add to Briefcase
View Summary IMAAGEN Data Demonstrate that Abiraterone Acetate Plus Prednisone (5mg once daily) Lowers PSA Levels in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer (M0-CRPC)
Jun 2, 2014
PDF 68.6 KB Add to Briefcase
View Summary Phase 3 Data Highlight Benefits of Using Velcade® Within Frontline Treatment of Mantle Cell Lymphoma, With Results Showing Significantly Longer Progression-Free Survival Compared to Standard of Care
Jun 1, 2014
PDF 59.9 KB Add to Briefcase
View Summary Ibrutinib (IMBRUVICA®) RESONATE Data Show Significant Improvements in Progression-Free Survival and Overall Survival in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
May 31, 2014
PDF 72.3 KB Add to Briefcase
View Summary Ibrutinib (IMBRUVICA®) Three Year Follow-up of Single-Agent and Combination Study Results in Chronic Lymphocytic Leukemia
May 31, 2014
PDF 120.2 KB Add to Briefcase
View Summary Johnson & Johnson Medical Devices & Diagnostics Businesses Expanding Market Leadership with Innovative Products and Customer-Focused Solutions
May 22, 2014
PDF 15.7 KB Add to Briefcase
View Summary Ethicon-Funded Study Confirming Long-Term Benefit of Bariatric Surgery for Control of Diabetes Published in New England Journal of Medicine
May 22, 2014
PDF 13.6 KB Add to Briefcase

= add release to Briefcase